November 9, 2026
What is the goal of this trial?
The goal is to look at the safety of the study drug BNT168 and learn how the immune systems of people living with and without HIV respond to it.
You may be able to join if you do not have HIV and*:
- Are between 18 and 50 years and in good health
- Have never received an HIV vaccine in another clinical trial
*This is not the complete list of eligibility items. Trial staff will check these and other factors to make sure you can join this trial.
What is the trial drug, and would I get it?
BNT168 is a messenger RNA (mRNA)-based vaccine. BNT168 does not contain virus or virus particles. BNT168 is a trial (investigational) drug, which means health authorities have not approved it for doctors to prescribe. There is no guarantee that national health authorities will approve it in the future. You will be randomly assigned to get 3 shots of either BNT168 or placebo (dummy drug) over a period of 2 months.
What will happen if I join?
You will be in the study for about 9 months. You will be asked to come to the study centre for up to 9 in-person visits and will have up to 10 phone calls with the study doctor or representative. You will be paid back for certain travel costs.
To learn more:
Email: info@chru.co.za
WhatsApp: 076 985 7305
Phone: 011 276 8800
CLINICAL HEALTH RESEARCH UNIT (CHRU)
A division of the Wits Health Consortium